Best Practice for Breast

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast+5 More
Best Practice - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at whether an internet-based app can help improve adherence to a cancer treatment regimen.

Eligible Conditions
  • Breast
  • erbB-2 Receptor
  • Hormone Receptor-Positive Breast Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Up to 1 year

Up to 1 year
Adherence
Feasibility (Acceptability)
Feasibility (Compliance)
Patient satisfaction

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Single Arm (internet intervention, best practice)
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Best Practice · No Placebo Group · N/A

Single Arm (internet intervention, best practice)Experimental Group · 4 Interventions: Internet-Based Intervention, Survey Administration, Questionnaire Administration, Best Practice · Intervention Types: Other, Other, Other, Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,005 Previous Clinical Trials
41,301,897 Total Patients Enrolled
3 Trials studying Breast
980 Patients Enrolled for Breast
Emory UniversityLead Sponsor
1,503 Previous Clinical Trials
2,706,557 Total Patients Enrolled
Deepthi Kodali, MBBSPrincipal InvestigatorEmory University Hospital/Winship Cancer Institute

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have started an aromatase inhibitor or Tamoxifen within less than or equal to six months prior to enrollment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.